Scarica l'app Stockscreener
1.39
8.55%
-0.13
Dopo l'orario di chiusura:
1.25
-0.14
-10.07%
Precedente Chiudi:
$1.52
Aprire:
$1.51
Volume 24 ore:
1.39M
Relative Volume:
1.28
Capitalizzazione di mercato:
$150.38M
Reddito:
$4.35M
Utile/perdita netta:
$-45.53M
Rapporto P/E:
-1.287
EPS:
-1.08
Flusso di cassa netto:
$-44.79M
1 W Prestazione:
-12.58%
1M Prestazione:
+10.32%
6M Prestazione:
+39.08%
1 anno Prestazione:
+53.27%
Intervallo 1D:
$1.37
$1.53
Intervallo di 1 settimana:
$1.37
$1.70
Portata 52W:
$0.681
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Nome
Lucid Diagnostics Inc
Settore
Industria
Telefono
212 949 4319
Indirizzo
360 MADISON AVENUE, NEW YORK
Confronta LUCD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.39 | 161.55M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Iniziato | BTIG Research | Buy |
| 2021-11-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Needham | Buy |
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Indexes | LUCD Stock News - GuruFocus
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - PR Newswire
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.50 Consensus Price Target from Brokerages - Defense World
Certain Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Certain Common Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Insider Buying: Dennis Matheis Acquires 350,000 Shares of Lucid Diagnostics Inc (LUCD) - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
Lucid Diagnostics Files Shelf Registration for Secondary Sale of 37 Million Shares by Convertible Note Holders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LU - GuruFocus
Lucid Diagnostics Files Prospectus For Potential Offer, Sale From Time To Time Of Up To 37 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential - Investing.com Nigeria
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight - Investing.com Australia
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight By Investing.com - Investing.com India
Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cantor Fitzgerald Reiterates “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzg - GuruFocus
Lucid Diagnostics signals expanded market reach and $41M pro forma cash following commercial and clinical advances - MSN
Lucid Diagnostics Reports Increased Losses Amid Revenue Decline - TipRanks
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cantor maintains Lucid Diagnostics stock with $2 target after Q1 results - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzgerald | LUCD Stock News - GuruFocus
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
PAVmed Q1 Earnings: $40M Cash Runway Powers Multi-Subsidiary Growth and Biopharma Entry Plans - Stock Titan
PAVmed Inc. SEC 10-Q Report - TradingView
Cantor maintains Lucid Diagnostics stock with $2 target after Q1 results By Investing.com - Investing.com South Africa
Lucid Diagnostics Q1 2025 Earnings Call Transcript - MarketBeat
Lucid Diagnostics (LUCD) Sees Strong Q1 Performance with Expanded Testing - GuruFocus
Earnings call transcript: Lucid Diagnostics Q1 2025 highlights growth and strategic expansion - Investing.com Nigeria
Lucid Diagnostics (LUCD) Stock: Needham Reiterates Buy Rating | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Misses Q1 Revenue Estimates, Focuses on Growth | LUCD Stock News - GuruFocus
Transcript : Lucid Diagnostics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: Lucid Diagnostics Q1 2025 highlights growth and strategic expansion By Investing.com - Investing.com South Africa
Lucid Diagnostics Provides Business Update and Reports First Qua - GuruFocus
Lucid Diagnostics Inc Q1 2025 Earnings: Revenue Falls Short at $0.8 Million, Missing Estimates of $1.28 Million - GuruFocus
Lucid Diagnostics Reports Q1 2025 Financial Results - TipRanks
Lucid Diagnostics reports Q1 adjusted EPS (16c), consensus (10c) - TipRanks
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results - Financial Times
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - Finansavisen
Lucid Diagnostics (LUCD) Stock: Needham Reiterates Buy Rating | - GuruFocus
Lucid Diagnostics Inc Azioni (LUCD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):